Developed through a collaboration between
OVERVIEW
How much do you know about the latest treatment advances in endometrial cancer? Join Dr Monk and Dr Barber on the Medscape Oncology/GOG Foundation, Inc., live webinar, Virtual Grand Rounds: Staying Up to Date With Endometrial Cancer, to find out. Dr Monk and Dr Barber will cover the latest clinical trial data, patient selection, adverse event management, and other clinical implications. Be prepared to ask your most pressing questions on endometrial cancer management!
GOAL STATEMENT
The goal of this activity is to increase clinicians' knowledge and competence regarding the management of patients with endometrial cancer through a recurring online webinar series, focused on analyzing existing and emerging data and integrating this information into clinical practice.
LEARNING OBJECTIVES
Upon completion of this activity, participants will: Have increased knowledge regarding the [LIST] [ITEM]Key clinical trial data in endometrial cancers[ITEM]Important biomarkers to help identify eligible patients with endometrial cancers to receive immunotherapy[/LIST] Have greater competence related to [LIST][ITEM]Selecting immunotherapy-based treatment for patients with endometrial cancer[ITEM]Mitigating immune-related adverse events (irAEs) in patients with endometrial cancer receiving immunotherapy[/LIST]
ACCREDITATION STATEMENT
In support of improving patient care, Medscape LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. [JALOGO] [MEDSCAPE]
[bold]For Physicians[/bold] Medscape, LLC designates this live activity for a maximum of 0.5 [italic][bold]AMA PRA Category 1 Credit(s)™[/bold][/italic]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Supported by an independent educational grant from [BOLD]Eisai Inc.[/BOLD]; [BOLD]Karyopharm Therapeutics[/BOLD]; [BOLD]Merck & Co., Inc.[/BOLD]